Dermapharm Holding SE (DMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Dermapharm Holding SE (DMP) has a cash flow conversion efficiency ratio of 0.054x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€39.49 Million ≈ $46.17 Million USD) by net assets (€735.17 Million ≈ $859.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see DMP market cap for the company's overall valuation and market capitalisation.
Dermapharm Holding SE - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Dermapharm Holding SE's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Dermapharm Holding SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dermapharm Holding SE ranked by their cash flow conversion efficiency. Explore Dermapharm Holding SE (DMP) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northwest Natural Gas Co
NYSE:NWN
|
0.074x |
|
LegoChem Biosciences Inc
KQ:141080
|
-0.093x |
|
Netmarble Games Corp
KO:251270
|
0.027x |
|
Shanghai Flyco Electrical Appliance Co Ltd
SHG:603868
|
0.085x |
|
Shenzhen Airport Co Ltd
SHE:000089
|
0.035x |
|
Timah Persero Tbk
JK:TINS
|
0.130x |
|
Mobileye Global Inc. Class A Common Stock
NASDAQ:MBLY
|
0.016x |
|
Aksa Enerji Uretim AS
IS:AKSEN
|
0.018x |
Annual Cash Flow Conversion Efficiency for Dermapharm Holding SE (2014–2025)
The table below shows the annual cash flow conversion efficiency of Dermapharm Holding SE from 2014 to 2025. View current stock price of Dermapharm Holding SE for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €701.83 Million ≈ $820.51 Million |
€181.51 Million ≈ $212.21 Million |
0.259x | -21.88% |
| 2024-12-31 | €608.29 Million ≈ $711.16 Million |
€201.38 Million ≈ $235.43 Million |
0.331x | -17.77% |
| 2023-12-31 | €545.05 Million ≈ $637.22 Million |
€219.42 Million ≈ $256.53 Million |
0.403x | -25.70% |
| 2022-12-31 | €532.49 Million ≈ $622.54 Million |
€288.53 Million ≈ $337.33 Million |
0.542x | +8.18% |
| 2021-12-31 | €499.83 Million ≈ $584.36 Million |
€250.37 Million ≈ $292.71 Million |
0.501x | +24.02% |
| 2020-12-31 | €324.58 Million ≈ $379.47 Million |
€131.10 Million ≈ $153.27 Million |
0.404x | +14.20% |
| 2019-12-31 | €284.49 Million ≈ $332.60 Million |
€100.61 Million ≈ $117.63 Million |
0.354x | -43.08% |
| 2018-12-31 | €256.08 Million ≈ $299.39 Million |
€159.13 Million ≈ $186.04 Million |
0.621x | -47.21% |
| 2017-12-31 | €73.69 Million ≈ $86.15 Million |
€86.74 Million ≈ $101.40 Million |
1.177x | -6.78% |
| 2016-12-31 | €60.81 Million ≈ $71.09 Million |
€76.78 Million ≈ $89.76 Million |
1.263x | +38.98% |
| 2015-12-31 | €44.44 Million ≈ $51.96 Million |
€40.38 Million ≈ $47.20 Million |
0.909x | -43.05% |
| 2014-12-31 | €34.01 Million ≈ $39.76 Million |
€54.26 Million ≈ $63.43 Million |
1.595x | -- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more